BPS Bioscience, Inc. Announces the Release of PCSK9 and LDLR Protein Products as well as Screening and Profiling Services

BPS continues its expansion of industry leading product and services offerings that help enable drug discovery for pharmaceutical companies and research institutions worldwide.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend

SAN DIEGO, CA (PRWEB) November 04, 2012

BPS Bioscience, Inc. (“BPS”) announced today the availability of PCSK9 and LDLR proteins, a PCSK9-LDLR Binding Assay Kit, and PCSK9 Screening/Profiling Services for cholesterol-related research. PCSK9 is a critical regulator of cholesterol metabolism through its interaction with the hepatic LDL receptor (LDLR). Circulating PCSK9 binds to the extracellular EGF-like domain of LDLR, followed by endocytosis and lysosomal degradation of the PCSK9-LDLR complex. Inhibiting the PCSK9-LDLR interaction is an increasingly desirable drug target for lowering LDL-cholesterol levels because of the great demand for new drugs to replace or supplement statins. The newly added research tools are invaluable for studying cholesterol metabolism, atherosclerosis, stroke, heart disease, and other diseases related to cardiovascular disorders. They complement the broad array of protein products and world class custom biochemical services already offered by BPS.

To learn more about these products, visit the BPS website (http://www.bpsbioscience.com) or email info(at)bpsbioscience(dot)com.

About BPS Bioscience
Headquartered in San Diego, California, the heart of one of the world's largest clusters of life science research institutes and companies, BPS Bioscience, Inc. is a leading producer for: Acetyltransferases, Bromodomains, Cytokines, HDACs, Histone Demethylases, Histone Methyltransferases, Kinases, , Phosphatases, Phosphodiesterases, Poly ADP Ribose Polymerases, Proteases, and Ubiquitin Enzymes. BPS offers one of the largest selections of recombinant enzymes and assay kits for drug discovery and continues to expand its portfolio of innovative drug discovery products. BPS also provides custom protein expression, biochemical and cell-based assays, and compound screening and profiling services. BPS has provided products and services to pharmaceutical companies and academic institutes in over 45 countries worldwide. By being at the forefront of technology development, BPS focuses on providing quality life science products and services in a timely manner that will help our customers to accelerate drug discovery and development for treatment of human diseases. Visit BPS’s website for more information: http://www.bpsbioscience.com.


Contact

  • Henry Zhu
    BPS Bioscience
    858-829-3082
    Email